Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01982448 (A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Platinum chemotherapy for early triple-negative breast cancer.Breast (Edinburgh, Scotland) · 2024Pooled it
- Platinum-based chemotherapy for early triple-negative breast cancer.The Cochrane database of systematic reviews · 2023Pooled it
- A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Breast (Edinburgh, Scotland) · 2022Pooled it
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.Cell reports. Medicine · 2026Trial
- Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).Journal of the National Cancer Institute · 2026Trial
- Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Article
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Homologous recombination deficiency correlates with tumor-infiltrating lymphocytes and predicts patient outcomes in hormone receptor-positive/HER2-negative breast cancer.Therapeutic advances in medical oncology · 2026Article
- Homologous recombination pathway alterations in basal-like breast cancer.Frontiers in oncology · 2026Review
- Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- DirectHRD enables sensitive scar-based classification of homologous recombination deficiency.Nucleic acids research · 2025Article
- Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.bioRxiv : the preprint server for biology · 2025Article
- Comprehensive review of male breast cancer: Understanding a rare condition.Oncology research · 2025Review
- Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring.Frontiers in oncology · 2025Review
- BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.British journal of cancer · 2024Review
- DNA damage response in breast cancer and its significant role in guiding novel precise therapies.Biomarker research · 2024Review
- Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients.Thoracic cancer · 2024Article
- Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 1 country.
Funding
Abstract
backgroundCisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. PATIENTS AND
methodsThis prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response.
resultsOne hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39-23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19-4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy.
conclusionsIn this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.